Article
A phase 1 trial of fuzuloparib in combination with apatinib for advanced ovarian and triple-negative breast cancer: efficacy, safety, pharmacokinetics and germline BRCA mutation analysis.
BMC medicine - 29 Sept 2023
Liu Yaxin, Wang Wei, Yin Rutie, Zhang Youzhong, Zhang Yu, Zhang Keqiang, Pan Hongming, Wang Ke, Lou Ge, Li Guiling, Zhang Ruyan, Li Kun, Rao Jing, Zhang Ben, Wang Yuting, Wang Quanren, Gao Yunong, Li Huiping
Abstract excerpt
BACKGROUND: The effect of the combination of an anti-angiogenic agent with a poly (ADP-ribose) polymerase (PARP) inhibitor in cancer treatment is unclear. We assessed the oral combination of fuzuloparib, a PARP inhibitor, and apatinib, a VEGFR2 inhibitor for treating advanced ovarian cancer (OC) or triple-negative breast cancer (TNBC). METHODS: This dose-escalation and pharmacokinetics-expansion phase 1 trial was...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.